Patent SG-11201907583T-A (SG)
Title: Methods for treating complement-mediated diseases and disorders
Inventor: VAN VLASSELAER PETER
IPC: C07K16/18
Filed: 2018-03-14
Abstract: ON O O (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 20 September 2018 (20.09.2018) WIPO I PCT mu °million °nolo olomollm olomunom oimIE (10) International Publication Number WO 2018/170145 Al (51) International Patent Classification: C07K 16/18 (2006.01) A61P 37/06 (2006.01) A61K 39/395 (2006.01) (21) International Application Number: PCT/US2018/022462 (22) International Filing Date: 14 March 2018 (14.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/471,190 14 March 2017 (14.03.2017) US 62/553,059 31 August 2017 (31.08.2017) US (71) Applicant: BIOVERATIV USA INC. [US/US]; 951 Gate- way Boulevard, South San Francisco, California 94080 (US). (72) Inventors: VAN VLASSELAER, Peter; 108 Crescent Avenue, Portola Valley, California 94028 (US). PAR- RY, Graham; 951 Gateway Boulevard, South San Fran- cisco, California 94080 (US). STAGLIANO, Nancy E.; 951 Gateway Boulevard, South San Francisco, California 94080 (US). PANICKER, Sandip; 951 Gateway Boule- vard, South San Francisco, California 94080 (US). (74) Agent: KIM, Ji-Eun et al.; Sterne, Kessler, Goldstein & Fox P.L.L.C., 1100 New York Avenue, NW, Washington, District of Columbia 20005 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) (54) Title: METHODS FOR TREATING COMPLEMENT-MEDIATED DISEASES AND DISORDERS (57) : The present disclosure provides methods of treating a complement-mediated disease or disorder in an individual, and methods of inhibiting activation of complement component C4 in an individual in need thereof. The methods comprise administering to the individual an anti-Cls antibody. The methods also comprise administering an anti-Cls antibody in a fixed dose, e.g., 5.5 g, 6.5 g, or 7.5 g. The methods also comprise administering an effective dose of an anti-Cls antibody to the individual to achieve a minimum serum level of anti-Cls antibody for therapeutic effect.